




- (51) **International Patent Classification:**
C07D 471/04 (2006.01) *A61K 31/437* (2006.01)
- (21) **International Application Number:**
PCT/SG2014/000601
- (22) **International Filing Date:**
17 December 2014 (17.12.2014)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
1322334.2 17 December 2013 (17.12.2013) GB
- (71) **Applicant:** AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis, Singapore 138632 (SG).
- (72) **Inventors:** ALAM, Jenefer; Experimental Therapeutics Centre, 11 Biopolis Way, #03-10/11, Helios, Singapore 138667 (SG). POULSEN, Anders; Experimental Therapeutics Centre, 11 Biopolis Way, #03-10/11, Helios, Singapore 138667 (SG). HO, Soo Yei; Experimental Therapeutics Centre, 11 Biopolis Way, #03-10/11, Helios, Singapore 138667 (SG). WANG, Wei Ling; Experimental Therapeutics Centre, 11 Biopolis Way, #03-10/11, Helios, Singapore 138667 (SG). DURAI SWAMY, Athisayamani Jeyaraj; Experimental Therapeutics Centre, 11 Biopolis Way, #03-10/11, Helios, Singapore 138667 (SG).
- (74) **Agent:** SPRUSON & FERGUSON (ASIA) PTE LTD; P.O. Box 1531, Robinson Road Post Office, Singapore 903031 (SG).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) **Title:** MALEIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY

(I)

(57) **Abstract:** The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein R₁ represents optionally substituted alkyl (wherein optional substituents include one or more substituents each independently selected from C₁₋₆alkoxy); optionally substituted carbocyclyl (wherein optional substituents include one or more substituents each independently selected from C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆haloalkyl, C₁₋₆haloalkoxy and halo); or -alkylaryl; R₂ represents H; or alkyl; R₃ represents H; or alkyl; U, V and W represent -(CH₂)_n; or U and V together represent -CH=CH- and W represents C=O; Y represents aryl; heteroaryl; optionally substituted carbocyclyl (wherein optional substituents include one or more substituents each independently selected from C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆haloalkyl, C₁₋₆haloalkoxy and halo); or optionally substituted heterocyclyl (wherein optional substituents include one or more substituents each independently selected from C₁₋₆alkyl, C₁₋₆alkoxy, -C(O)OC₁₋₆alkyl, -C(O)C₁₋₆alkyl and -C(O)NHC₁₋₆alkyl); and Z represents aryl; heteroaryl; optionally substituted carbocyclyl (wherein optional substituents include one

or more substituents each independently selected from C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆haloalkyl, C₁₋₆haloalkoxy and halo); or optionally substituted heterocyclyl (wherein optional substituents include one or more substituents each independently selected from C₁₋₆alkyl, C₁₋₆alkoxy, -C(O)OC₁₋₆alkyl, -C(O)C₁₋₆alkyl and -C(O)NHC₁₋₆alkyl).



(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*